Neogenomics (NEO) Net Income towards Common Stockholders (2010 - 2026)

Neogenomics (NEO) has 17 years of Net Income towards Common Stockholders data on file, last reported at $2.2 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 104.96% year-over-year to $2.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$51.9 million (up 50.14% YoY) and the FY2025 annual result came in at -$108.0 million, down 37.22% from the prior year.
• Net Income towards Common Stockholders climbed to $2.2 million in Q2 2026, from -$17.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.2 million in Q2 2026 to a low of -$49.4 million in Q1 2022.
• A 5-year average of -$24.1 million and a median of -$23.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 146.53% — and 2026, when it jumped 104.96%.
• Tracing NEO's Net Income towards Common Stockholders over 5 years: stood at -$22.7 million in 2022, then jumped by 36.85% to -$14.3 million in 2023, then decreased by 6.97% to -$15.3 million in 2024, then soared by 35.52% to -$9.9 million in 2025, then surged by 122.65% to $2.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $2.2 million (Q2 2026), -$17.1 million (Q1 2026), and -$9.9 million (Q4 2025), per Business Quant data.